Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F12%3A12617" target="_blank" >RIV/00216208:11110/12:12617 - isvavai.cz</a>
Alternative codes found
RIV/00023728:_____/12:#0004127
Result on the web
<a href="http://rheumatology.oxfordjournals.org/content/51/7/1226" target="_blank" >http://rheumatology.oxfordjournals.org/content/51/7/1226</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX
Original language description
CZP 400 mg every 4 weeks plus MTX was administred to paetints with rheumatid arthritis. ACR20 response rates were 45.9% vs 22.9% in patients treated only with methotrexate.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FE - Other fields of internal medicine
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Rheumatology
ISSN
1462-0324
e-ISSN
—
Volume of the periodical
51
Issue of the periodical within the volume
7
Country of publishing house
GB - UNITED KINGDOM
Number of pages
9
Pages from-to
1226-1234
UT code for WoS article
000305631500013
EID of the result in the Scopus database
—